Generic placeholder image

当代肿瘤药物靶点

Editor-in-Chief

ISSN (Print): 1568-0096
ISSN (Online): 1873-5576

Research Article

HHLA2 作为结直肠癌新治疗靶点的临床意义

卷 24, 期 11, 2024

发表于: 30 January, 2024

页: [1177 - 1186] 页: 10

弟呕挨: 10.2174/0115680096290709240102064645

价格: $65

摘要

背景:结直肠癌(Colorectal cancer, CRC)是一种在世界范围内具有高致死率、高独立性的消化系统恶性肿瘤。 目标:研究结果有望为发现结直肠癌新的治疗靶点提供重要的理论依据。 方法:采用Western blot检测6例CRC患者切除的新鲜组织中HHLA2的表达,包括癌组织、癌旁组织和正常组织。采用免疫组化染色法检测139例结直肠癌石蜡包埋标本中HHLA2的表达,并分析其与临床病理及生存的关系。利用靶向HHLA2的小干扰RNA (siRNA)转染CRC细胞使HHLA2沉默。采用MTT法、平板集落形成法、细胞划痕法和Transwell法观察结直肠癌细胞的增殖、迁移和侵袭情况。 结果:HHLA2蛋白在人结直肠癌组织、癌旁组织和正常组织中均有表达,在癌组织中表达量显著上调(P < 0.01)。HHLA2在结直肠癌组织中的表达水平与肿瘤浸润深度(P = 0.000)、区域淋巴结转移(P = 0.018)、临床分期(P = 0.010)、患者生存率(P = 0.011)密切相关。与性别(P = 0.873)、年龄(P = 0.864)、肿瘤部位(P = 0.768)、肿瘤分化程度(P = 0.569)、远处转移(P = 0.494)的相关性无统计学意义。HHLA2高表达组和低表达组CRC患者的生存时间分别为43.231个月和55.649个月,两组差异有统计学意义(P = 0.001)。沉默HHLA2可显著抑制结直肠癌细胞的增殖、迁移和侵袭。 结论:HHLA2在结直肠癌组织中过表达,与患者预后不良有关。HHLA2可能被认为是CRC辅助诊断和预后的新候选者,也是CRC免疫治疗的新靶点。

关键词: 结直肠癌,HHLA2,临床病理特征,siRNA, western blot,预后。

« Previous
图形摘要
[1]
Malvicini, M.; Gutierrez-Moraga, A.; Rodriguez, M.M.; Gomez-Bustillo, S.; Salazar, L.; Sunkel, C.; Nozal, L.; Salgado, A.; Hidalgo, M.; Lopez-Casas, P.P.; Novella, J.L.; Vaquero, J.J.; Alvarez-Builla, J.; Mora, A.; Gidekel, M.; Mazzolini, G. A tricin derivative from deschampsia antarctica Desv. Inhibits colorectal carcinoma growth and liver metastasis through the induction of a specific immune response. Mol. Cancer Ther., 2018, 17(5), 966-976.
[http://dx.doi.org/10.1158/1535-7163.MCT-17-0193] [PMID: 29483221]
[2]
Garden, O. J.; Rees, M.; Poston, G. J.; Mirza, D.; Saunders, M.; Ledermann, J.; Primrose, J. N.; Parks, R. W. Guidelines for resection of colorectal cancer liver metastases. Gut, 2006, 55(S3), iii1-iii8.
[http://dx.doi.org/10.1136/gut.2006.098053]
[3]
Bray, F.; Ferlay, J.; Soerjomataram, I.; Siegel, R.L.; Torre, L.A.; Jemal, A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin., 2018, 68(6), 394-424.
[http://dx.doi.org/10.3322/caac.21492] [PMID: 30207593]
[4]
Besharati, F.; Karimi-Shahanjarini, A.; Hazavehei, S.M.M.; Bashirian, S.; Bagheri, F.; Faradmal, J. Development of a colorectal cancer screening intervention for iranian adults: Appling intervention mapping. Asian Pac. J. Cancer Prev., 2017, 18(8), 2193-2199.
[PMID: 28843255]
[5]
Wild, A.T.; Yamada, Y. Treatment options in oligometastatic disease: Stereotactic body radiation therapy - focus on colorectal cancer. Visc. Med., 2017, 33(1), 54-61.
[http://dx.doi.org/10.1159/000454685] [PMID: 28612018]
[6]
Zhou, Q.H.; Li, K.W.; Chen, X.; He, H.X.; Peng, S.M.; Peng, S.R.; Wang, Q.; Li, Z.A.; Tao, Y.R.; Cai, W.L.; Liu, R.Y.; Huang, H. HHLA2 and PD-L1 co-expression predicts poor prognosis in patients with clear cell renal cell carcinoma. J. Immunother. Cancer, 2020, 8(1), e000157.
[http://dx.doi.org/10.1136/jitc-2019-000157] [PMID: 31959726]
[7]
Rieder, S.A.; Wang, J.; White, N.; Qadri, A.; Menard, C.; Stephens, G.; Karnell, J.L.; Rudd, C.E.; Kolbeck, R. B7-H7 (HHLA2) inhibits T-cell activation and proliferation in the presence of TCR and CD28 signaling. Cell. Mol. Immunol., 2021, 18(6), 1503-1511.
[http://dx.doi.org/10.1038/s41423-020-0361-7] [PMID: 32005952]
[8]
Lin, G.; Ye, H.; Wang, J.; Chen, S.; Chen, X.; Zhang, C. Immune checkpoint human endogenous retrovirus-H long terminal repeat-associating protein 2 is upregulated and independently predicts unfavorable prognosis in bladder urothelial carcinoma. Nephron J., 2019, 141(4), 256-264.
[http://dx.doi.org/10.1159/000495887] [PMID: 30602154]
[9]
Zhu, Z.; Dong, W. Overexpression of HHLA2, a member of the B7 family, is associated with worse survival in human colorectal carcinoma. OncoTargets Ther., 2018, 11, 1563-1570.
[http://dx.doi.org/10.2147/OTT.S160493] [PMID: 29593422]
[10]
Mo, R.H.; Zaro, J.L.; Ou, J.H.J.; Shen, W.C. Effects of Lipofectamine 2000/siRNA complexes on autophagy in hepatoma cells. Mol. Biotechnol., 2012, 51(1), 1-8.
[http://dx.doi.org/10.1007/s12033-011-9422-6] [PMID: 21660602]
[11]
Escande, C.; Nin, V.; Price, N.L.; Capellini, V.; Gomes, A.P.; Barbosa, M.T.; O’Neil, L.; White, T.A.; Sinclair, D.A.; Chini, E.N. Flavonoid apigenin is an inhibitor of the NAD+ ase CD38: Implications for cellular NAD+ metabolism, protein acetylation, and treatment of metabolic syndrome. Diabetes, 2013, 62(4), 1084-1093.
[http://dx.doi.org/10.2337/db12-1139] [PMID: 23172919]
[12]
Taratula, O.; Garbuzenko, O.B.; Chen, A.M.; Minko, T. Innovative strategy for treatment of lung cancer: targeted nanotechnology-based inhalation co-delivery of anticancer drugs and siRNA. J. Drug Target., 2011, 19(10), 900-914.
[http://dx.doi.org/10.3109/1061186X.2011.622404] [PMID: 21981718]
[13]
Zhang, M.; Qiu, B.; Sun, M.; Wang, Y.; Wei, M.; Gong, Y.; Yan, M. Preparation of Black pepper (Piper nigrum L.) essential oil nanoparticles and its antitumor activity on triple negative breast cancer in vitro. J. Food Biochem., 2022, 46(12), e14406.
[http://dx.doi.org/10.1111/jfbc.14406] [PMID: 36121189]
[14]
Lucafò, M.; Curci, D.; Franzin, M.; Decorti, G.; Stocco, G. Inflammatory bowel disease and risk of colorectal cancer: An overview from pathophysiology to pharmacological prevention. Front. Pharmacol., 2021, 12, 772101.
[http://dx.doi.org/10.3389/fphar.2021.772101] [PMID: 34744751]
[15]
Xue, L.; Williamson, A.; Gaines, S.; Andolfi, C.; Paul-Olson, T.; Neerukonda, A.; Steinhagen, E.; Smith, R.; Cannon, L.M.; Polite, B.; Umanskiy, K.; Hyman, N. An update on colorectal cancer. Curr. Probl. Surg., 2018, 55(3), 76-116.
[http://dx.doi.org/10.1067/j.cpsurg.2018.02.003] [PMID: 29631699]
[16]
Cao, H.; Xu, E.; Liu, H.; Wan, L.; Lai, M. Epithelial–mesenchymal transition in colorectal cancer metastasis: A system review. Pathol. Res. Pract., 2015, 211(8), 557-569.
[http://dx.doi.org/10.1016/j.prp.2015.05.010] [PMID: 26092594]
[17]
Abbott, M.; Ustoyev, Y. Cancer and the immune system: The history and background of immunotherapy. Semin. Oncol. Nurs., 2019, 35(5), 150923.
[http://dx.doi.org/10.1016/j.soncn.2019.08.002] [PMID: 31526550]
[18]
Marcus, A.; Gowen, B.G.; Thompson, T.W.; Iannello, A.; Ardolino, M.; Deng, W.; Wang, L.; Shifrin, N.; Raulet, D.H. Recognition of tumors by the innate immune system and natural killer cells. Adv. Immunol., 2014, 122, 91-128.
[http://dx.doi.org/10.1016/B978-0-12-800267-4.00003-1] [PMID: 24507156]
[19]
Im, A.; Pavletic, S.Z. Immunotherapy in hematologic malignancies: Past, present, and future. J. Hematol. Oncol., 2017, 10(1), 94.
[http://dx.doi.org/10.1186/s13045-017-0453-8] [PMID: 28434396]
[20]
Nixon, N.A.; Blais, N.; Ernst, S.; Kollmannsberger, C.; Bebb, G.; Butler, M.; Smylie, M.; Verma, S. Current landscape of immunotherapy in the treatment of solid tumours, with future opportunities and challenges. Curr. Oncol., 2018, 25(5), 373-384.
[http://dx.doi.org/10.3747/co.25.3840] [PMID: 30464687]
[21]
Zhao, R.; Chinai, J.M.; Buhl, S.; Scandiuzzi, L.; Ray, A.; Jeon, H.; Ohaegbulam, K.C.; Ghosh, K.; Zhao, A.; Scharff, M.D.; Zang, X. HHLA2 is a member of the B7 family and inhibits human CD4 and CD8 T-cell function. Proc. Natl. Acad. Sci., 2013, 110(24), 9879-9884.
[http://dx.doi.org/10.1073/pnas.1303524110] [PMID: 23716685]
[22]
Zhong, C.; Lang, Q.; Yu, J.; Wu, S.; Xu, F.; Tian, Y. Phenotypical and potential functional characteristics of different immune cells expressing CD28H/B7-H5 and their relationship with cancer prognosis. Clin. Exp. Immunol., 2020, 200(1), 12-21.
[http://dx.doi.org/10.1111/cei.13413] [PMID: 31901178]
[23]
Janakiram, M.; Chinai, J.M.; Fineberg, S.; Fiser, A.; Montagna, C.; Medavarapu, R.; Castano, E.; Jeon, H.; Ohaegbulam, K.C.; Zhao, R.; Zhao, A.; Almo, S.C.; Sparano, J.A.; Zang, X. Expression, clinical significance, and receptor identification of the newest B7 family member HHLA2 protein. Clin. Cancer Res., 2015, 21(10), 2359-2366.
[http://dx.doi.org/10.1158/1078-0432.CCR-14-1495] [PMID: 25549724]
[24]
Janakiram, M.; Chinai, J.M.; Zhao, A.; Sparano, J.A.; Zang, X. HHLA2 and TMIGD2: New immunotherapeutic targets of the B7 and CD28 families. OncoImmunology, 2015, 4(8), e1026534.
[http://dx.doi.org/10.1080/2162402X.2015.1026534] [PMID: 26405587]
[25]
Farrag, M.; Ibrahim, E.; El-Hadidy, T.; Akl, M.; Elsergany, A.; Abdelwahab, H. Human endogenous retrovirus-H long terminal repeat- associating protein 2 (HHLA2) is a novel immune checkpoint protein in lung cancer which predicts survival. Asian Pac. J. Cancer Prev., 2021, 22(6), 1883-1889.
[http://dx.doi.org/10.31557/APJCP.2021.22.6.1883] [PMID: 34181347]

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy